Low molecular weight heparin

Aniara Diagnostica would like to announce the availability of Biophen Anti-Xa and Biophen Anti-IIa, two-stage Chromogenic Assays

Retrieved on: 
Thursday, January 16, 2020
Heparins, Chemistry, Physical sciences, Natural sciences, Low molecular weight heparin, Assay, UFH

WEST CHESTER, Ohio, Jan. 16, 2020 /PRNewswire-PRWeb/ -- Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today's highest Industrial QC Heparin standards.

Key Points: 
  • WEST CHESTER, Ohio, Jan. 16, 2020 /PRNewswire-PRWeb/ -- Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today's highest Industrial QC Heparin standards.
  • These products are for Research Use Only and not for use in Diagnostic procedures.
  • These kits are two stage chromogenic assay used for measuring the activity of heparins (UFH or LMWH) in a manual or automated method.

Analysis on the World's Heparin Market, 2019-2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 22, 2019
Health, Pharmaceutical, Heparins, RTT, Glycosaminoglycans, Chemical substances, Chemistry, Medicine, Medication, Low molecular weight heparin

The "Heparin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Heparin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.
  • The global heparin market is expected to grow at a CAGR of around 5% during 2019-2024.
  • Furthermore, biopharmaceutical companies are developing innovative medicines to enhance the therapeutic potential of heparin and reduce its side-effects.
  • How has the global heparin market performed so far and how will it perform in the coming years?

FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots

Retrieved on: 
Thursday, May 16, 2019
Medicine, Clinical medicine, Health, RTT, Heparins, Anticoagulants, Priority review, Food and Drug Administration, Low molecular weight heparin

"Prior to this approval, there had been no FDA-approved therapies to treat VTE in pediatric patients.

Key Points: 
  • "Prior to this approval, there had been no FDA-approved therapies to treat VTE in pediatric patients.
  • Given the unmet need, we granted the Fragmin application priority review and today we are approving it as the first anticoagulant (blood thinner) indicated for pediatric patients.
  • Fragmin was initially approved by the FDA in 1994 for adults and is a type of heparin, which works as an anticoagulant.
  • Health care professionals are advised to monitor patients closely for bleeding when administering Fragmin to patients who currently take anticoagulants.

Venous Thromboembolism Treatment Market is Expected to Observe a CAGR of 4.0% Over 2019 to 2029 - Future Market Insights

Retrieved on: 
Wednesday, May 15, 2019
Hematology, Medical specialties, Medicine, Venous thrombosis, Thrombosis, Deep vein thrombosis, Embolism, Superficial thrombophlebitis, Low molecular weight heparin

As indicated by a recent Future Market Insights (FMI) study, the market revenues will observe approximately 4% CAGR between 2019 and 2029.

Key Points: 
  • As indicated by a recent Future Market Insights (FMI) study, the market revenues will observe approximately 4% CAGR between 2019 and 2029.
  • Based on the disease indication, deep vein thrombosis is expected to hold a prominent share in the overall venous thromboembolism treatment market .
  • The first and the most important factor driving the venous thromboembolism treatment market is the increasing prevalence of venous thromboembolism disease.
  • Apart from the driving factors of venous thromboembolism treatment market, there are few factors that are likely to hinder the overall growth of the venous thromboembolism treatment market.

Venous Thromboembolism Treatment Market is Expected to Observe a CAGR of 4.0% Over 2019 to 2029 - Future Market Insights

Retrieved on: 
Wednesday, May 15, 2019
Hematology, Medical specialties, Medicine, Venous thrombosis, Thrombosis, Deep vein thrombosis, Embolism, Superficial thrombophlebitis, Low molecular weight heparin

As indicated by a recent Future Market Insights (FMI) study, the market revenues will observe approximately 4% CAGR between 2019 and 2029.

Key Points: 
  • As indicated by a recent Future Market Insights (FMI) study, the market revenues will observe approximately 4% CAGR between 2019 and 2029.
  • Based on the disease indication, deep vein thrombosis is expected to hold a prominent share in the overall venous thromboembolism treatment market .
  • The first and the most important factor driving the venous thromboembolism treatment market is the increasing prevalence of venous thromboembolism disease.
  • Apart from the driving factors of venous thromboembolism treatment market, there are few factors that are likely to hinder the overall growth of the venous thromboembolism treatment market.

Global Thrombosis Drugs Market Forecast up to 2024: Focus on Factor Xa Inhibitors, Low Molecular Weight Heparin & P2Y12 Platelet Inhibitors - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2019
Health, Cardiology, Pharmaceutical, Blood, Hematology, Medical specialties, Medicine, Anticoagulants, Heparins, RTT, Coagulation system, Thrombosis, Low molecular weight heparin, Direct Xa inhibitor, Venous thrombosis

The thrombosis drugs market by drug class is segmented into factor Xa inhibitor, low molecular weight heparin, and P2Y12 platelet inhibitor.

Key Points: 
  • The thrombosis drugs market by drug class is segmented into factor Xa inhibitor, low molecular weight heparin, and P2Y12 platelet inhibitor.
  • The factor Xa inhibitor segment occupied a significant market share in 2017 and is expected to grow at a high CAGR during the forecast period.
  • The thrombosis drugs market by indication is segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis.
  • North America is the major shareholder in the global thrombosis drugs market, followed by Europe.

Global Anticoagulants Industry

Retrieved on: 
Tuesday, January 22, 2019
Heparins, Medicine, Clinical medicine, RTT, Blood, Blood tests, Glycosaminoglycans, Anticoagulant, Low molecular weight heparin

Table 58: German 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Key Points: 
  • Table 58: German 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    Table 61: Italian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    Table 64: The UK 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    Table 67: Spanish 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    Table 70: Russian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    Table 71: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    Table 73: Rest of Europe 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2
    Table 74: Over 65 Years Individuals as % of the Total Population in Select Asian Countries: 2016 (includes corresponding Graph/Chart)
    Table 75: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    Table 76: Asia-Pacific Historic Review for Anticoagulants by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2
    Table 77: Asia-Pacific 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    Table 80: Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2

The global anticoagulants market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025

Retrieved on: 
Thursday, December 13, 2018
Medicine, Blood tests, Blood, Heparins, Anticoagulants, Hematology, Medical signs, RTT, Low molecular weight heparin, Vitamin K antagonist, Coagulation, Vitamin K

Anticoagulants, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood and prolong the clotting time.

Key Points: 
  • Anticoagulants, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood and prolong the clotting time.
  • The market has different types of anticoagulant drugs, and each drug works by inhibiting various pathways of blood coagulation.
  • On the basis of drug class, the anticoagulants market is classified as NOACs, heparin & LMWH, vitamin K antagonist, and others.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Aniara Diagnostica Launches Heparinassay.com Providing Specific Product Information for Quality Control (QC) Measurement of Heparin and Its Analogues

Retrieved on: 
Thursday, October 4, 2018
Coagulation system, Blood, Heparins, Chemistry, Anatomy, Factor X, Thrombin, Chromogenic, Assay, Low molecular weight heparin

USP/EP Compliant Heparin QC Kits Chromogenic Anti-IIa and Anti-Xa methods are used for measuring homogeneous Heparin for Quality Control.

Key Points: 
  • USP/EP Compliant Heparin QC Kits Chromogenic Anti-IIa and Anti-Xa methods are used for measuring homogeneous Heparin for Quality Control.
  • Heparin Anti-IIa (Kinetics) BIOPHEN Heparin Anti-IIa (Kinetics) is a method for measuring Heparin in purified systems.
  • Chromogenic Substrates: Thrombin Chromogenic Substrates for use in the Anti-IIa assay for Quality Control.
  • Chromogenic Substrates: Factor Xa Factor Xa Chromogenic Substrates for use in the Anti-Xa assay for Quality Control.

Guillain-Barré Syndrome Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Retrieved on: 
Wednesday, May 23, 2018
Medicine, Clinical medicine, Marketing, Economy, RTT, Anticonvulsants, GABAA receptor positive allosteric modulators, Sodium channel blockers, Low molecular weight heparin, Market segmentation, Distribution, Marketplace

It also provides the overall information and data analysis of the global GuillainBarr syndrome market with respect to the leading market segments based on therapeutics, route of administration, distribution channel, and geography.

Key Points: 
  • It also provides the overall information and data analysis of the global GuillainBarr syndrome market with respect to the leading market segments based on therapeutics, route of administration, distribution channel, and geography.
  • Based on therapeutics, the GuillainBarr syndrome market has been segmented into intravenous immunoglobulin, plasma exchange, and others (analgesics, anticonvulsants, LMWH, etc.).
  • In terms of distribution channel, the GuillainBarr syndrome market has been divided into hospital pharmacies, retail pharmacies, and others (home care, clinics, etc.).
  • All these factors may help market players to take strategic decisions in order to strengthen their position and increase their share in the global GuillainBarr syndrome market.